Thu, Feb 27, 9:02 PM (52 days ago)
**Summary of Cardiff Oncology, Inc. (CRDF) 10-K Report for Fiscal Year Ended December 31, 2024** Cardiff Oncology, Inc. reported a net loss of approximately $45.5 million for FY 2024, compared to $41.5 million in FY 2023. Revenue increased slightly to $0.7 million, primarily from sales-based royalties unrelated to its lead product candidate, onvansertib. Research and development expenses rose by $4 million to $36.9 million, reflecting increased clinical trial costs. The company ended the year with $91.7 million in cash and cash equivalents, sufficient to fund operations into 2027. Onvansertib, a selective PLK1 inhibitor, is under investigation for various cancers, including RAS-mutated metastatic colorectal cancer (mCRC). The company is focusing on advancing its clinical trials, with significant milestones anticipated in 2025. Risks include reliance on third-party vendors for clinical trials, regulatory approvals, and market acceptance of its products. The company has raised $40 million through a registered direct offering and has secured patents to protect its intellectual property. However, it faces challenges such as ongoing losses, capital needs, and potential volatility in its stock price.